The high positive rate of IGF2BP2 in ESCC also makes future use of chemotherapeutic agents or radionuclides coupled to the peptide for ESCC therapy an attractive prospect, which has been stated in earlier studies [27]. The gene discussed is IGF2BP2; the disease is esophageal squamous cell carcinoma.